Volatile Stock in List: Agenus Inc (AGEN)

Currently Agenus Inc (NASDAQ:AGEN)'s shares owned by insiders are 1.9%, whereas shares owned by institutional owners are 45.9%. The company now has a Return on Equity (ROE) of 0 and a Return on Investment (ROI) of 1.2. The ratio is more positive, as 43 investment managers increased or started new holdings, while 32 sold and reduced their holdings in Agenus Inc. Similar statistics are true for the second largest owner, Rtw Investments, Lp, which owns 4,218,520 shares of the stock are valued at $16.83 million.

At the end of 09/30/2017 reporting period, 41 institutional holders increased their position in Agenus Inc. It increased, as 14 investors sold AGEN shares while 18 reduced holdings. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. This public company's current market capitalization stands at $320.51 million. The firm offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. The business's revenue was down 24.4% on a year-over-year basis. equities analysts expect that Agenus will post -1.16 earnings per share for the current fiscal year. In fact, Agenus received a boost when Merck selected its lead antibody candidate and several backup antibodies for an undisclosed checkpoint target. Voya Investment Management LLC now owns 40,855 shares of the biotechnology company's stock valued at $160,000 after purchasing an additional 6,381 shares during the last quarter. Agenus Inc. (AGEN) average trading volume of 1,463,665 during the past month is 23.15% above its average volume over the past year, indicating that investors have been more active than usual in the stock in recent times. 6,546 Agenus Inc. (NASDAQ:AGEN) shares with value of $22,651 were sold by Duncan Alex. It has underperformed by 18.96% the S&P500.

In the past 52-week period, shares of Agenus Inc.

Agenus (NASDAQ:AGEN) last issued its earnings results on Tuesday, November 7th. (NASDAQ:AGEN). Moreover, Venbio Select Advisor Limited has 0.84% invested in Agenus Inc. However the low revenue estimates for the company are $3.56 Million versus high revenue estimates of $27.6 Million. The Luxembourg-based Artal Group S.A. has invested 0.19% in the stock. Schwab Charles Inv Inc, a California-based fund reported 282,015 shares.

Grizzlies' Mike Conley (heel) to undergo season-ending surgery
He has averaged just 17.1 points and 4.1 assists to go with a career-low 38.1 shooting percentage in 2017-18. The team says they expect he'll a full recovery prior to 2018-19 training camp.

Jurgen Klopp: More Liverpool signings in January 'not likely'
We couldn't see anywhere where we could go, where we would be better off than Liverpool . Both sides have a number of injury concerns ahead of the clash at Anfield .

Florida Mayor Removed From Office After FBI Sting
The agents recorded the meetings, and Cooper told them she had two other people working with her to work their influence. After a series of transactions, the agents revealed their identities to Koslow in August 2013 - but didn't arrest him.

Since January 1, 0001, it had 0 insider buys, and 5 sales for $95,988 activity. BidaskClub downgraded Agenus from a "hold" rating to a "sell" rating in a report on Saturday, December 9th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Agenus has a 12 month low of $3.20 and a 12 month high of $5.45. The stock now has an average rating of "Hold" and an average price target of $5.81. Agenus had 10 analyst reports since July 27, 2015 according to SRatingsIntel.

In other news, CEO Garo H. Armen acquired 100,000 shares of Agenus stock in a transaction dated Monday, October 30th. Zacks Investment Research raised Agenus from a "hold" rating to a "buy" rating and set a $4.25 target price for the company in a research note on Wednesday, October 25th. On Monday, July 27 the stock rating was maintained by MLV with "Buy". Jefferies maintained the stock with "Buy" rating in Friday, July 29 report. (NASDAQ:AGEN) has "Buy" rating given on Monday, June 26 by Jefferies. The firm earned "Buy" rating on Friday, March 11 by Maxim Group. On Wednesday, March 9 the stock rating was maintained by JMP Securities with "Market Outperform". The rating was downgraded by Maxim Group to "Hold" on Tuesday, October 27. Jefferies maintained the stock with "Buy" rating in Thursday, August 3 report. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Closes $230 Million Royalty Monetization with HealthCare Royalty ..." published on January 22, 2018 as well as Fool.com's news article titled: "Why Agenus Inc. Stock Sank in December" on January 06, 2018, also Fool.com with their article: "Will 2018 Be Agenus Inc.'s Best Year Yet?" published on January 16, 2018, Prnewswire.com published: "Agenus Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.